Advertisement

Tumor Biology

, Volume 37, Issue 3, pp 3581–3588 | Cite as

High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer

  • Baoying Yuan
  • Changshun Wu
  • Xingwen Wang
  • Dan Wang
  • Huiling Liu
  • Ling Guo
  • Xiang-An LiEmail author
  • Junqing HanEmail author
  • Hong FengEmail author
Original Article

Abstract

Scavenger receptor class B type I (SR-BI) has been linked to the development and progression of breast cancer. However, its clinical significance in breast cancer remains unclear. Here, we evaluated SR-BI expression in a well-characterized breast cancer tissue microarray by immunohistochemistry. High SR-BI expression was observed in 54 % of all breast cancer cases and was significantly associated with advanced pTNM stage (P = 0.002), larger tumor size (P = 0.023), lymph node metastasis (P = 0.012), and the absence of ER (P = 0.014). The Kaplan–Meier survival analysis revealed that patients with high SR-BI expression had significantly shorter overall survival (OS) (P = 0.004). Moreover, multivariate analysis with adjustment for other prognostic factors confirmed that SR-BI was an independent prognostic factor for patient outcome (P = 0.017). Overall, our study demonstrated that high SR-BI expression was related to conventional parameters indicative of more aggressive tumor type and may serve as a new prognostic marker for poor clinical outcome in human breast cancer.

Keywords

Breast cancer Scavenger receptor class B type I Prognosis Immunohistochemistry 

Notes

Supplementary material

13277_2015_4141_MOESM1_ESM.docx (229 kb)
ESM 1 (DOCX 228 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6(6):229–39.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    de Lorgeril M, Salen P. Helping women to good health: breast cancer, omega-3/omega-6 lipids, and related lifestyle factors. BMC Med. 2014;12:54.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Thompson HJ, Sedlacek SM, Paul D, Wolfe P, McGinley JN, Playdon MC, et al. Effect of dietary patterns differing in carbohydrate and fat content on blood lipid and glucose profiles based on weight-loss success of breast-cancer survivors. Breast Cancer Res. 2012;14(1):R1.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Muntoni S, Atzori L, Mereu R, Satta G, Macis MD, Congia M, et al. Serum lipoproteins and cancer. Nutr Metab Cardiovasc Dis. 2009;19(3):218–25.CrossRefPubMedGoogle Scholar
  6. 6.
    Calvo D, Vega MA. Identification, primary structure, and distribution of CLA-1, a novel member of the CD36/LIMPII gene family. J Biol Chem. 1993;268(25):18929–35.PubMedGoogle Scholar
  7. 7.
    Murao K, Terpstra V, Green SR, Kondratenko N, Steinberg D, Quehenberger O. Characterization of CLA-1, a Human Homologue of Rodent Scavenger Receptor BI, as a Receptor for High Density Lipoprotein and Apoptotic Thymocytes. J Biol Chem. 1997;272(28):17551–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Cao G, Garcia CK, Wyne KL, Schultz RA, Parker KL, Hobbs HH. Structure and localization of the human gene encoding SR-BI/CLA-1. Evidence for transcriptional control by steroidogenic factor 1. J Biol Chem. 1997;272(52):33068–76.CrossRefPubMedGoogle Scholar
  9. 9.
    Cao WM, Murao K, Imachi H, Yu X, Abe H, Yamauchi A, et al. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res. 2004;64(4):1515–21.CrossRefPubMedGoogle Scholar
  10. 10.
    Krieger M. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Investig. 2001;108(6):793–7.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Guo L, Song Z, Li M, Wu Q, Wang D, Feng H, et al. Scavenger Receptor BI Protects against Septic Death through Its Role in Modulating Inflammatory Response. J Biol Chem. 2009;284(30):19826–34.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Li Y, Kakinami C, Li Q, Yang B, Li H. Human apolipoprotein A-I is associated with dengue virus and enhances virus infection through SR-BI. PLoS One. 2013;8(7), e70390.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    McGrowder D, Riley C, Morrison EY, Gordon L: The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer. Cholesterol 2011, 2011:496925.Google Scholar
  14. 14.
    Vilchez JA, Martinez-Ruiz A, Sancho-Rodriguez N, Martinez-Hernandez P, Noguera-Velasco JA. The real role of prediagnostic high-density lipoprotein cholesterol and the cancer risk: a concise review. Eur J Clin Invest. 2014;44(1):103–14.CrossRefPubMedGoogle Scholar
  15. 15.
    Wadsack C, Hirschmugl B, Hammer A, Levak-Frank S, Kozarsky KF, Sattler W, et al. Scavenger receptor class B, type I on non-malignant and malignant human epithelial cells mediates cholesteryl ester-uptake from high density lipoproteins. Int J Biochem Cell Biol. 2003;35(4):441–54.CrossRefPubMedGoogle Scholar
  16. 16.
    Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, et al. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate. 2010;70(4):390–400.PubMedGoogle Scholar
  17. 17.
    Shahzad MMK, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, et al. Targeted Delivery of Small Interfering RNA Using Reconstituted High-Density Lipoprotein Nanoparticles. Neoplasia. 2011;13(4):309–IN308.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Zheng Y, Liu Y, Jin H, Pan S, Qian Y, Huang C, et al. Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles. Theranostics. 2013;3(7):477–86.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Danilo C, Gutierrez-Pajares JL, Mainieri MA, Mercier I, Lisanti MP, Frank PG. Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development. Breast Cancer Res. 2013;15(5):R87.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987;8(3):138–40.PubMedGoogle Scholar
  21. 21.
    Llaverias G, Danilo C, Mercier I, Daumer K, Capozza F, Williams TM, et al. Role of cholesterol in the development and progression of breast cancer. Am J Pathol. 2011;178(1):402–12.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Danilo C, Frank PG. Cholesterol and breast cancer development. Curr Opin Pharmacol. 2012;12(6):677–82.CrossRefPubMedGoogle Scholar
  23. 23.
    Pussinen PJ, Karten B, Wintersperger A, Reicher H, McLean M, Malle E, et al. The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake. Biochem J. 2000;349(Pt 2):559–66.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Pan B, Ren H, Lv X, Zhao Y, Yu B, He Y, et al. Hypochlorite-induced oxidative stress elevates the capability of HDL in promoting breast cancer metastasis. J Transl Med. 2012;10:65.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Pan B, Ren H, Ma Y, Liu D, Yu B, Ji L, et al. High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. Int J Cancer. 2012;131(1):70–82.CrossRefPubMedGoogle Scholar
  26. 26.
    Saddar S, Carriere V, Lee WR, Tanigaki K, Yuhanna IS, Parathath S, et al. Scavenger receptor class B type I is a plasma membrane cholesterol sensor. Circ Res. 2013;112(1):140–51.CrossRefPubMedGoogle Scholar
  27. 27.
    Silver DL, Tall AR. The cellular biology of scavenger receptor class B type I. Curr Opin Lipidol. 2001;12(5):497–504.CrossRefPubMedGoogle Scholar
  28. 28.
    Antalis CJ, Arnold T, Rasool T, Lee B, Buhman KK, Siddiqui RA. High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res Treat. 2010;122(3):661–70.CrossRefPubMedGoogle Scholar
  29. 29.
    Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001;7(7):853–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Martin JH, Begum S Fau - Alalami O, Alalami O Fau - Harrison A, Harrison A Fau - Scott KW, Scott KW: Endothelial nitric oxide synthase: correlation with histologic grade, lymph node status and estrogen receptor expression in human breast cancer. (1010–4283 (Print)).Google Scholar
  31. 31.
    Loibl S, Strank C, von Minckwitz G, Sinn HP, Buck A, Solbach C, et al. Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer. Breast. 2005;14(3):230–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer. 2006;6(7):521–34.CrossRefPubMedGoogle Scholar
  33. 33.
    Lahdenranta J, Hagendoorn J, Padera TP, Hoshida T, Nelson G, Kashiwagi S, et al. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res. 2009;69(7):2801–8.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, et al. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res. 2006;12(4):1201–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Lacko AG, Nair M, Paranjape S, Johnso S, McConathy WJ. High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 2002;22(4):2045–9.PubMedGoogle Scholar
  36. 36.
    Medina-Echeverz J, Fioravanti J, Diaz-Valdes N, Frank K, Aranda F, Gomar C, et al. Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases. PLoS One. 2014;9(5), e96799.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Yang S, Damiano MG, Zhang H, Tripathy S, Luthi AJ, Rink JS, et al. Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Sci U S A. 2013;110(7):2511–6.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs. 2008;19(2):183–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Mooberry LK, Nair M, Paranjape S, McConathy WJ, Lacko AG. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target. 2010;18(1):53–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Han J, Parsons M, Zhou X, Nicholson AC, Gotto Jr AM, Hajjar DP. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation. 2004;110(22):3472–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Zhao SP, Wu ZH, Hong SC, Ye HJ, Wu J. Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits. Clin Chim Acta; Int J Clin Chem. 2006;365(1–2):119–24.CrossRefGoogle Scholar
  42. 42.
    Tsuruoka H, Khovidhunkit W, Brown BE, Fluhr JW, Elias PM, Feingold KR. Scavenger receptor class B type I is expressed in cultured keratinocytes and epidermis. Regulation in response to changes in cholesterol homeostasis and barrier requirements. J Biol Chem. 2002;277(4):2916–22.CrossRefPubMedGoogle Scholar
  43. 43.
    Kimura T, Mogi C, Tomura H, Kuwabara A, Im DS, Sato K, et al. Induction of Scavenger Receptor Class B Type I Is Critical for Simvastatin Enhancement of High-Density Lipoprotein-Induced Anti-Inflammatory Actions in Endothelial Cells. J Immunol. 2008;181(10):7332–40.CrossRefPubMedGoogle Scholar
  44. 44.
    Briand F, Magot T Fau - Krempf M, Krempf M Fau - Nguyen P, Nguyen P Fau - Ouguerram K, Ouguerram K: Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs. (0014–2972 (Print)).Google Scholar
  45. 45.
    de Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, et al. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis. 2008;197(1):57–63.CrossRefPubMedGoogle Scholar
  46. 46.
    Mardones P, Pilon A, Bouly M, Duran D, Nishimoto T, Arai H, et al. Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. J Biol Chem. 2003;278(10):7884–90.CrossRefPubMedGoogle Scholar
  47. 47.
    Lan D, Silver DL. Fenofibrate induces a novel degradation pathway for scavenger receptor B-I independent of PDZK1. J Biol Chem. 2005;280(24):23390–6.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Cancer CenterShandong Provincial Hospital affiliated to Shandong University, Shandong UniversityJinanChina
  2. 2.Department of OrthopedicsShandong Provincial Hospital affiliated to Shandong University, Shandong UniversityJinanChina
  3. 3.Department of Central LabShandong Provincial Hospital affiliated to Shandong UniversityJinanChina
  4. 4.Department of Pediatrics, Saha Cardiovascular Research CenterUniversity of Kentucky College of MedicineLexingtonUSA

Personalised recommendations